EXEL Reports STELLAR-303 Results
Exelixis reports final STELLAR-303 analysis showing non-significant OS trend favoring zanzalintinib and Tecentriq combo in non-liver metastases mCRC
Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC